As­traZeneca COPD drug fi­nal­ly gets OK from FDA, inch­ing clos­er to GSK leader

Al­most a year ago, As­traZeneca’s triple-drug com­bi­na­tion for chron­ic ob­struc­tive pul­monary dis­ease was shot down with an FDA com­plete re­sponse let­ter. But on Fri­day, it fi­nal­ly re­ceived the green light.

The UK phar­ma gi­ant has re­ceived ap­proval for its Breztri Aeros­phere, for­mer­ly dubbed PT010, cul­mi­nat­ing the drug’s bumpy reg­u­la­to­ry jour­ney in a win. Now, As­traZeneca can chal­lenge the leader in the area — Glax­o­SmithK­line’s Trel­e­gy — with­out ob­sta­cle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER